Percutaneous Thermal Ablation in RCC: Evidence Review and Future Perspectives

For T1a renal cell carcinoma (≤3 cm), percutaneous thermal ablation offers comparable cancer-specific survival to partial nephrectomy, with better renal function preservation but higher local recurrence; salvage ablation effectively treats residual tumors.

• For T1a RCC (≤3 cm), thermal ablation modalities (MWA, RFA, cryoablation) show similar therapeutic efficacy and safety profiles.
• Compared to partial nephrectomy, TA yields better renal function preservation and fewer complications, but higher local recurrence; cancer-specific survival is comparable.
• Additional ablation for residual tumors is effective; preprocedural embolization and hydrodissection may enhance safety and efficacy.

Automated summary

RadPigeon summaries are original and for information only. They are not clinical advice.